Abstracts tagged "proteomics and rheumatoid arthritis (RA)"

Abstract Number: 2051 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Factor Peptide Expression By Quantitative Proteomics Delineates Responsive and Resistant Clones after Treatment of Early Rheumatoid Arthritis
Jing Jing Wang¹, William Murray-Brown², Alexander Colella¹, Malcolm D. Smith³, Tim Chataway⁴, Jenny Walker², William H. Robinson⁵, Mihir D Wechalekar² and Tom Gordon^1,6, ¹Immunology, Flinders University, Adelaide, Australia, ²Rheumatology, Flinders University, Adelaide, Australia, ³Rheumotology, Flinders University, Adelaide, Australia, ⁴Proteomic Facility, Flinders University, Adelaide, Australia, ⁵Stanford University, Palo Alto, CA, ⁶Immunology, SA Pathology, Adelaide, Australia
Background/Purpose: Rheumatoid factors (RFs) are associated with disease activity and joint damage in rheumatoid arthritis (RA) and thought to play a pathogenic role in disease.…
Abstract Number: 583 • 2018 ACR/ARHP Annual Meeting
Identification of a Protein Profile Useful to Predict Response to Methotrexate in Early Rheumatoid Arthritis Patients
Cristina Ruiz-Romero¹, Florencia Picchi², Lucia González², Rebecca Hands³, Valentina Calamia², Patricia Fernández⁴, Maria Camacho², Rocío Paz², Conrad Bessant⁵, Costantino Pitzalis³ and Francisco J Blanco⁶, ¹Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ²Rheumatology Research Group, Proteomics Unit-ProteoRed/ISCIII, INIBIC-CHUAC, A Coruña, Spain, ³Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ⁴Proteomics group, Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, La Coruña, Spain, ⁵School of Biological and Chemical Sciences, Queen Mary University of London, London, United Kingdom, ⁶Rheumatology Divison, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain
Background/Purpose: Among the best known disease-modifying antirheumatic drugs, Methotrexate (MTX) is one of the most effective and widely used medications. It is used as a…
Abstract Number: 1467 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Activity Monitoring and Multiplex Biomarker Verification By Tageted Proteomics
Lucía González-Rodríguez¹, Valentina Calamia¹, Patricia Fernández², Cristina Ruiz-Romero³, Antonio Julià⁴, Antonio Fernández-Nebro⁵, Jesús Tornero⁶, Sara Marsal⁴ and Francisco J Blanco³, ¹Proteomics Group, Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ²Proteomics group, Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, La Coruña, Spain, ³Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ⁴Rheumatology Research Group, Vall d’Hebron Hospital Research Institute, Barcelona, Spain., Barcelona, Spain, ⁵UGC Reumatología, Instituto de Investigación Biomédica (IBIMA), Hospital Regional Universitario de Málaga, Spain., Málaga, Spain, ⁶Hospital Universitario Guadalajara, Guadalajara, Spain., Guadalajara, Spain
Background/Purpose: Rheumatoid arthritis (RA) is a long-lasting inflammatory autoimmune disorder that ultimately leads to the destruction of joint architecture. The activity of this disease is…
Abstract Number: 1019 • 2017 ACR/ARHP Annual Meeting
Molecular Profiling of RA Patients Suggests a Differential Involvement of Adaptive and Innate Cell Populations in Response to Anti-TNF Treatment
Victor Farutin¹, Thomas Prod'homme¹, Kevin McConnell¹, Nathaniel Washburn¹, Patrick Halvey¹, Jamey Guess¹, Nur Sibel Gunay¹, Jan Hillson², Carol J. Etzel³, Katherine C. Saunders³, Dimitrios A. Pappas^3,4, Anthony Manning¹, Leona Ling¹ and Ishan Capila¹, ¹Research, Momenta Pharmaceuticals, Inc., Cambridge, MA, ²Clinical Research, Momenta Pharmaceuticals, Inc., Cambridge, MA, ³Corrona, LLC, Southborough, MA, ⁴Columbia University, New York, NY
Background/Purpose: Despite the success of anti-TNF therapies in RA, ~ 30 % of patients are non-responders. Several studies have focused on understanding the biology underlying…
Abstract Number: 1358 • 2017 ACR/ARHP Annual Meeting
Relationship between Serum Protein Pattern and High Disease Activity in Patients with Rheumatoid Arthritis
Pavel Horak¹, Anna Petráčková², Martina Skácelová³, Eva Kriegová⁴, Petra Schneiderová⁵ and František Mrázek⁵, ¹III. Department of internal medicine, III. Department of Internal Medicine, Faculty of Medicine and Dentistry, Palacký University of Olomouc, Olomouc, Czech Republic, ²Department of Immunology, Department of Immunology, Faculty of Medicine and Dentistry, Palacky University of Olomouc, Olomouc, Czech Republic, ³III. Department of Internal Medicine, Faculty of Medicine and Dentistry, Palacký University of Olomouc, Olomouc, Czech Republic, ⁴Department of Immunology,, Faculty of Medicine and Dentistry, Palacky University of Olomouc, Olomouc, Czech Republic, ⁵Department of Immunology, Faculty of Medicine and Dentistry, Palacky University of Olomouc, Olomouc, Czech Republic
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease that primarily affects joints. There is still limited information of serum biomarkers suitable for effective monitoring…
Abstract Number: 595 • 2015 ACR/ARHP Annual Meeting
Discovery of Serum Protein Biomarkers of Response to Adalimumab in Rheumatoid Arthritis and Their Relationship to Biomarkers of Response to Infliximab
Ignacio Ortea¹, Bernd Roschitzki², Eva Tomero³, Juan G. Ovalles-Bonilla⁴, Javier Lopez-Longo⁵, Inmaculada de la Torre⁵, Isidoro Gonzalez-Alvaro⁶, Juan J Gomez-Reino⁷ and Antonio Gonzalez⁸, ¹Maimónides Health Research Institute (IMIBIC), Cordoba, Spain, ²Functional Genomics Center Zurich, University and ETH Zurich, Zurich, Switzerland, ³Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ⁴Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁵Gregorio Marañon Hospital, Madrid, Spain, ⁶Hospital Univ. de La Princesa, IIS Princesa, Madrid, Spain, ⁷Instituto Investigacion Sanitaria- Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ⁸Laboratorio Investigacion 10 and Rheumatology Unit, Instituto Investigacion Sanitaria- Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain
Background/Purpose: Biomarkers of response to treatment in rheumatoid arthritis (RA) are sorely needed given the large inter-individual variability in efficacy of the available drugs. However,…
Abstract Number: 2092 • 2014 ACR/ARHP Annual Meeting
Proteomic Phenotyping of Rheumatoid Arthritis Disease Activity
Yauheniya Cherkas, Sarah Lamberth, Carrie Brodmerkel and Mark Curran, Janssen Research & Development, LLC., Spring House, PA
Background/Purpose The use of objective biomarkers of clinical disease characteristics such as disease activity would be beneficial in informing patients, physicians and payers. Recently, a…
Abstract Number: 2579 • 2012 ACR/ARHP Annual Meeting
Novel Autoantibodies to 14-3-3 Eta Are Highly Specific for Rheumatoid Arthritis
Walter P. Maksymowych¹, Désirée van der Heijde², R. Landewe³, Vivian P. Bykerk⁴ and Anthony Marotta⁵, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁴Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Augurex Life Sciences Corp, North Vancouver, BC, Canada
Background/Purpose: Serum 14-3-3 eta, a protein biomarker that is differentially expressed in rheumatoid arthritis (RA), has been reported to add incrementally to rheumatoid factor (RF)…
Abstract Number: 1691 • 2012 ACR/ARHP Annual Meeting
Early Signs of Subclinical Inflammation and Local Antibody Production in Early Rheumatoid Lungs
Gudrun Reynisdottir¹, Reza Karimi², Jimmy Ytterberg³, Vijay Joshua¹, Helga Olsen², Aase Haj Hensvold¹, Anders Harju⁴, Johan Grunewald², Sven Nyren⁵, Anders Eklund², Lars Klareskog⁶, Roman Zubarev⁷, Magnus Skold² and Anca Catrina¹, ¹Department of Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ²Department of Medicine, Division of Respiratory Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ³Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ⁵Radiology, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, Stockholm, Sweden, ⁶Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, ⁷Karolinska Institutet, Stockholm, Sweden
Background/Purpose: The aims of the current study was to investigate if inflammatory lung changes are present in RA patients early in the disease process and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].